TABLE 1.
Clinical and Pathological Characteristics of the NIH Cohort and Distribution of PD-L1 Expression
| PD-L1 IHC (SP263) n(%) | ||||
|---|---|---|---|---|
| Total n = 183a | ≥1% n = 54 (29.5) | ≥5% n = 43 (23.4) | ≥25% n = 28 (15.3) | |
| Age (yr) | ||||
| Median (range) | 48 (4-75) | 52 (4-74) | 53 (18-74) | 53 (23-74) |
| Sex | ||||
| Female | 57 (31) | 16 (30) | 14 (33) | 6 (21) |
| Male | 124 (69) | 38 (70) | 29 (67) | 22 (79) |
| Presentation | ||||
| Primaryb | 46 (25) | 13 (24) | 11 (26) | 9 (3) |
| Recurrent/post-therapy | 137 (75) | 41 (76) | 32 (74) | 19 (68) |
| Diagnosis (WHO 2016) | ||||
| LGG | 6 (3.3) | 0 (0) | 0 (0) | 0 (0) |
| AA, IDHmut | 21 (11.6) | 1 (1.8) | 0 (0) | 0 (0) |
| AO, IDH-mut/1p19q codeleted | 5 (2.7) | 2 (3.7) | 1 (2.3) | 1 (3.6) |
| Glioblastoma, IDHwt | 81 (44.2) | 37 (68.5) | 30 (69.7) | 20 (71.4) |
| Glioblastoma, IDHmut | 13 (7.1) | 2 (3.7) | 1 (2.3) | 0 (0) |
| Glioblastoma, NOS | 31 (16.9) | 12 (22.2) | 11 (25.6) | 7 (25) |
| DMG, H3K27Mmut | 16 (8.8) | 0 (0) | 0 (0) | 0 (0) |
LGG, low-grade (diffuse) glioma (WHO grade II); AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; DMG, diffuse midline glioma.
an = 5 cases did not have available clinical information.
bPrior to chemotherapy or radiotherapy.
Glioblastoma, NOS: WHO grade IV diffuse gliomas with negative IDH R132H staining and an alternative IDH1 or IDH2 mutation probability between 11 and 89%.
Not shown: AANOS (not otherwise specified, n = 2); AAIDHwt (n = 1); AOANOS (anaplastic oligoastrocytoma, n = 1); AONOS (n = 1); DMG non-H3K27M (n = 5).